Skip to main content
Have a personal or library account? Click to login
Forced Vital Capacity and Six-Minute Walk Test as Indicators of Interstitial Lung Disease Extent on High-Resolution Computed Tomography in Systemic Sclerosis Cover

Forced Vital Capacity and Six-Minute Walk Test as Indicators of Interstitial Lung Disease Extent on High-Resolution Computed Tomography in Systemic Sclerosis

Open Access
|Sep 2026

References

  1. ALTHOBIANI MA, RUSSELL AM, JACOB J, RANJAN Y, FOLARIN AA, HURST JR, et al. Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Front Med (Lausanne). 2024;11:1296890.
  2. SHAO T, SHI X, YANG S, ZHANG W, LI X, SHU J, et al. Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations. Front Immunol. 2021;12:684699.
  3. BERNSTEIN EJ, JAAFAR S, ASSASSI S, DOMSIC RT, FRECH TM, GORDON JK, et al. Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2020;72(11):1892–6.
  4. LESCOAT A, HUSCHER D, SCHOOF N, AIRÒ P, DE VRIES-BOUWSTRA J, RIEMEKASTEN G, et al. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. Rheumatology (Oxford). 2023;62(6):2178–88.
  5. QIU M, NIAN X, PANG L, YU P, ZOU S. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: a systematic review and meta-analysis. Int J Rheum Dis. 2021;24(12):1449–59.
  6. COTTIN V, BROWN KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019;20(1):13.
  7. TYNDALL AJ, BANNERT B, VONK M, AIRÒ P, COZZI F, CARREIRA PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–15.
  8. GOH NSL, DESAI SR, VEERARAGHAVAN S, HANSELL DM, COPLEY SJ, MAHER TM, et al. Interstitial lung disease in systemic sclerosis. Am J Respir Crit Care Med. 2008;177(11):1248–54.
  9. RUBIO-RIVAS M, ROBLES-ANGELES P, CORBELLA X, et al. Prevalence and characteristics of extensive versus limited systemic sclerosis-associated interstitial lung disease: systematic review and meta-analysis. Semin Arthritis Rheum. 2024;65:152373.
  10. FAIRLEY JL, GOH NSL, NIKPOUR M. Systemic sclerosis-associated interstitial lung disease: diagnostic approaches and challenges. Rev Colomb Reumatol. 2024;31 Suppl 1:S15–25.
  11. JOHNSON SR, BERNSTEIN EJ, BOLSTER MB, CHUNG JH, DANOFF SK, GEORGE MD, et al. 2023 ACR/CHEST guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024;76(8):1201–13.
  12. CARON M, HOA S, HUDSON M, SCHWARTZMAN K, STEELE R. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. Eur Respir Rev. 2018;27(147):170102.
  13. HOFFMANN-VOLD AM, AALØKKEN TM, LUND MB, GAREN T, MIDTVEDT Ø, BRUNBORG C, et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol. 2015;67(8):2205–12.
  14. SULIMAN YA, DOBROTA R, HUSCHER D, NGUYEN-KIM TDL, MAURER B, JORDAN S, et al. Pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol. 2015;67(12):3256–61.
  15. SUMPHAO-NGERN P, FOOCHAROEN C, BOONSAWAT W, MAHAKKANUKRAUH A, SUWANNAROJ S, SAE-OUE U, et al. Causes and prevalence of inadequate pulmonary function testing among patients with systemic sclerosis. Arch Med Sci. 2015;11(6):1255–60.
  16. SURESH S, NAGESH NJ, SURIYAN S, TALATAM RP. Correlation of six-minute walk test and lung function test variables in patients with connective tissue disorder-associated interstitial lung disease. J Evol Med Dent Sci. 2020;9(37):2690–4.
  17. PERELAS A, SILVER RM, ARROSSI AV, HIGHLAND KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304–20.
  18. DAS A, KUMAR A, ARROSSI AV, GHOSH S, HIGHLAND KB. Scleroderma-related interstitial lung disease: principles of management. Expert Rev Respir Med. 2019;13(4):357–67.
  19. DISTLER O, ASSASSI S, COTTIN V, CUTOLO M, DANOFF SK, DENTON CP, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020;55(5):1902026.
  20. GOH NS, HOYLES RK, DENTON CP, HANSELL DM, RENZONI EA, MAHER TM, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017;69(8):1670–8.
  21. DISTLER O, HIGHLAND KB, GAHLEMANN M, AZUMA A, FISCHER A, MAYES MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–28.
  22. RIZZI M, RADOVANOVIC D, SANTUS P, AIROLDI A, FRASSANITO F, VANNI S, et al. Usefulness of six-minute walk test in systemic sclerosis. Clin Exp Rheumatol. 2018;36 Suppl 113(4):161–7.
  23. MIRSAEIDI M, BARLETTA P, GLASSBERG MK. Systemic sclerosis associated interstitial lung disease: new directions in disease management. Front Med (Lausanne). 2019;6:248.
  24. ELHAI M, HOFFMANN-VOLD AM, AVOUAC J, PEZET S, CAUVET A, LEBLOND A, et al. Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2019;71(6):972–82.
  25. HOFFMANN-VOLD AM, FRETHEIM H, HALSE AK, SEIP M, BITTER H, WALLENIUS M, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med. 2019;200(10):1258–66.
  26. CHENIVESSE C, BOULANGER S, LANGLOIS C, WEMEAU-STERVINOU L, PEREZ T, WALLAERT B. Oxygen desaturation during a 6-minute walk test as a predictor of maximal exercise-induced gas exchange abnormalities in sarcoidosis. J Thorac Dis. 2016;8(8):1995–2003.
  27. SOMEYA F, MUGII N, HASEGAWA M, YAHATA T, NAKAGAWA T. Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease. Respir Care. 2014;59(1):75–80.
  28. DEL GALDO F, LESCOAT A, CONAGHAN PG, BERTOLDO E, ČOLIĆ J, SANTIAGO T, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025;84(1):29–40.
  29. GRAHAM BL, STEENBRUGGEN I, MILLER MR, BARJAKTAREVIC IZ, COOPER BG, HALL GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70–88.
  30. ATS COMMITTEE ON PROFICIENCY STANDARDS FOR CLINICAL PULMONARY FUNCTION LABORATORIES. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.
  31. VAN DEN HOOGEN F, KHANNA D, FRANSEN J, JOHNSON SR, BARON M, TYNDALL A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–47.
DOI: https://doi.org/10.2478/rjim-2026-0018 | Journal eISSN: 2501-062X (formerly 1220-4749) | Journal ISSN: 1220-4749
Language: English, Romanian
Submitted on: Jun 15, 2026
Published on: Sep 7, 2026
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services

© 2026 Sahat Halim, Cleopas Martin Rumende, RM Suryo Anggoro Kusumo Wibowo, Aulia Rizka, Gurmeet Singh, Mohamad Syahrir Azizi, Kaka Renaldi, Saut Horas Hatoguan Nababan, Kuntjoro Harimurti, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.